PRENW
Prenetics Global Limited
NASDAQ · Healthcare · Medical - Diagnostics & Research · HK
$0.01
+0.00%Year over year
Reported trailing growth
- Revenue
- +167.7%
- EBITDA
- -8.3%
- EBIT
- -2.3%
- EPS
- -7.5%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +126.2%
- EBITDA
- +53.6%
- EPS
- +43.8%
Three-year CAGR
- Revenue
- +91.5%
- EBITDA
- +37.6%
- EBIT
- +20.8%
- Net income
- +18.6%
- EPS
- +26.4%
- Free cash flow
- +26.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026